Sign In
16 Apr 2010 13:17
NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS
VERNALIS PLC (the "Company")
16 April 2010
Vernalis plc (LSE: VER) announces that, in accordance with DTR 3.1.4R(1)(a) and following a resolution by the Board of Vernalis plc passed in accordance with the Vernalis Share Option Plan scheme arrangements approved by shareholders, the following options over the Company's ordinary shares, with a nominal value of 1 pence each, were today granted to the Executive Directors and other Persons Discharging Managerial Responsibilities who are members of the management committee ("PDMRs"):
|
Executive Director |
No of shares under option |
Exercise Price |
% of Issued Share Capital |
|
Ian Garland |
630,900 |
52.75 pence |
0.63 |
|
David Mackney |
388,246 |
52.75 pence |
0.39 |
|
PDMRs |
No of shares under option |
Exercise Price |
% of Issued Share Capital |
|
Mike Wood |
168,874 |
52.75 pence |
0.17 |
|
Stephen Pawsey |
145,592 |
52.75 pence |
0.15 |
|
Alison Hood |
116,474 |
52.75 pence |
0.12 |
The options are exercisable between three and ten years following grant provided that the performance conditions of the option scheme are met.
Enquiries:
|
Vernalis |
+44 (0) 118 989 9360 |
|
Ian Garland, Chief Executive Officer David Mackney, Chief Financial Officer
|
|
|
Brunswick Group |
+44 (0) 20 7404 5959 |
|
Jon Coles Justine McIlroy Will Carnwath |
|
About Vernalis:
Vernalis is a development stage pharmaceutical company with significant expertise in taking promising product candidates along a commercially-focused path to market. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eleven candidates in development, eight of which are designated priority programmes. Five of these priority programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Biogen Idec, Chiesi, Endo, GSK, Menarini, Novartis and Servier. For further information about Vernalis, please visit www.vernalis.com
Follow the stocks
